Novel simvastatin-loaded nanoparticles based on cholic acid-core star-shaped PLGA for breast cancer treatment

Journal of Biomedical Nanotechnology

Volumn 11, Issue 7, 2015, Pages 1247-1260

  Wu, Yanping ^a   Wang, Zhongyuan ^a   Liu, Gan ^b   Zeng, Xiaowei ^a   Wang, Xusheng ^a   Gao, Yongfeng ^a   Jiang, Lijuan ^a   Shi, Xiaojun ^a   Tao, Wei ^a   Huang, Laiqiang ^a   Mei, Lin ^a  

^a TSINGHUA UNIVERSITY   (China)

^b NANKAI UNIVERSITY   (China)

Author keywords

CA PLGA; Cancer nanotechnology; Drug delivery; Nanomedicine; Simvastatin

Indexed keywords

CHEMOTHERAPY; DISEASES; DRUG DELIVERY; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; TUMORS;

BREAST CANCER TREATMENT; CANCER NANOTECHNOLOGY; CONTROLLED DELIVERY; HUMAN BREAST CANCER CELLS; IMMUNOHISTOCHEMISTRY; POLY(D ,L-LACTIDE-CO-GLYCOLIDE); SIMVASTATIN; STAR-SHAPED POLYMER;

COPOLYMERS;

ANTINEOPLASTIC AGENT; CHOLIC ACID; LACTIC ACID; NANOCAPSULE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; SIMVASTATIN;

ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DIFFUSION; FEMALE; MOUSE; NEOPLASMS, EXPERIMENTAL; PARTICLE SIZE; PATHOLOGY; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHOLIC ACID; DIFFUSION; FEMALE; LACTIC ACID; MICE; MICE, INBRED BALB C; NANOCAPSULES; NEOPLASMS, EXPERIMENTAL; PARTICLE SIZE; POLYGLYCOLIC ACID; SIMVASTATIN; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 84918594933     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2015.2068     Document Type: Article

References (38)

1. J. Ferlay, H. R. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin, Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127, 2893 (2010).
2. L. Mei, Z. Zhang, L. Zhao, L. Huang, X. L. Yang, J. Tang, and S. S. Feng, Pharmaceutical nanotechnology for oral delivery of anticancer drugs. Adv. Drug Deliv. Rev. 65, 880 (2013).
3. M. S. Muthu, D. T. Leong, L. Mei, and S. S. Feng, Nanotheranostics < application and further development of nanomedicine strategies for advanced theranostics. Theranostics 4, 660. 2014
4. C. Wang, C. Long, C. Xie, X. Chen, L. Zhang, B. Chu, Y. Wang, F. Luo, and Z. Qian,Two malignant tumor.J Biomed. Nanotechnol. ,357 (2013)
5. B. Xue, Y. Wang, X. Tang, P. Xie, F. Luo, C. Wu, and Z. Qian, Biodegradable self-assembled MPEG-PCL micelles for hydrophobic oridonin delivery in vitro. J. Biomed. Nanotechnol. 8, 80 (2012).
6. M. Vert, Degradable and bioresorbable polymers in surgery and in pharmacology: Beliefs and facts. J Mater Sci. Mater Med. 20, 437 (2009).
7. C. Yang, L. Jiang, S. Bu, L. Zhang, X. Xie, Q. Zeng, D. Zhu, and Y. Zheng, Intravitreal administration of dexamethasone-loaded PLGA-TPGS nanoparticles for the treatment of posterior segment diseases. J Biomed. Nanotechnol. 9, 1617 (2013).
8. Y. Ouyang, C. Huang, Y. Zhu, C. Fan, and Q. Ke, Fabrication of seamless electrospun collagen/PLGA conduits whose walls comprise highly longitudinal aligned nanofibers for nerve regeneration. J Biomed. Nanotechnol. 9, 931 (2013).
9. R. Surolia, M. Pachauri, and P. C. Ghosh, Preparation and characterization of monensin loaded PLGA nanoparticles: In vitro anti-malarial activity against plasmodium falciparum. J Biomed. Nanotechnol. 8, 172 (2012).
10. S. Aggarwal, S. Yadav, and S. Gupta, EGFR targeted PLGA nanoparticles using gemcitabine for treatment of pancreatic cancer. J Biomed. Nanotechnol. 7, 137 (2011).
11. W. Park, D. Kim, H. C. Kang, Y. H. Bae, and K. Na, Multi-arm histidine copolymer for controlled release of insulin from poly(lactideco- glycolide) microsphere. Biomaterials 33, 8848 (2012).
12. C. P. Ouyang, Q. Liu, S. X. Zhao, G. L. Ma, Z. P. Zhang, and C. X. Song, Synthesis and characterization of star-shaped poly (lactideco- glycolide) and its drug-loaded microspheres. olym. Bull. 68, 27 (2012).
13. Z. Li, E. Kesselman, Y. Talmon, M. A. Hillmyer, and T. P. Lodge, Multicompartment micelles from ABC miktoarm stars in water. Science 306, 98 (2004).
14. L. Y. Qiu and Y. H. Bae, Polymer architecture and drug delivery. Pharm Res. 23, 1 (2006).
15. J. Cao, S. Y. Zhai, C. L. Li, B. He, Y. S. Lai, Y.W. Chen, X. L. Luo, and Z. W. Gu, Novel pH-sensitive micelles generated by star-shape copolymers containing zwitterionic sulfobetaine for efficient cellular internalization. J Biomed. Nanotechnol. 9, 1847 (2013).
16. G. Lapienis, Star-shaped polymers having PEO arms. Prog. Polym. Sci. 34, 852 (2009).
17. L. Mei, Y. Jiang, and S. S. Feng, Star-shaped block polymers as a molecular biomaterial for nanomedicine development. Nanomedicine (Lond) 9, 9 (2014).
18. F. Taylor, M. D. Huffman, A. F. Macedo, T. H. Moore, M. Burke, G. Davey Smith, K. Ward, and S. Ebrahim, Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 1, CD004816 (2013).
19. Z. Wang, Y. Wu, H. Wang, Y. Zhang, L. Mei, X. Fang, X. Zhang, F. Zhang, H. Chen, Y. Liu, Y. Jiang, S. Sun, Y. Zheng, N. Li, and L. Huang, Interplay of mevalonate and hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Proc. Natl. Acad Sci. U S A. (2013).
20. M. F. Demierre, P. D. Higgins, S. B. Gruber, E. Hawk, and S. M. Lippman, Statins and cancer prevention. Nat. Rev. Cancer. 5, 930 (2005).
21. M. Osmak, Statins and cancer: Current and future prospects. Cancer Lett. 324, 1 (2012).
22. J. W. Clendening and L. Z. Penn, Targeting tumor cell metabolism with statins. Oncogene 31, 4967 (2012).
23. M. Thurnher, O. Nussbaumer, and G. Gruenbacher, Novel aspects of mevalonate pathway inhibitors as antitumor agents. Clin. Cancer Res. 18, 3524 (2012).
24. M. J. Campbell, L. J. Esserman, Y. Zhou, M. Shoemaker, M. Lobo, E. Borman, F. Baehner, A. S. Kumar, K. Adduci, C. Marx, E. F. Petricoin, L. A. Liotta, M. Winters, S. Benz, and C. C. Benz, Breast cancer growth prevention by statins. Cancer Res. 66, 8707 (2006).
25. W. A. Freed-Pastor, H. Mizuno, X. Zhao, A. Langerod, S. H. Moon, R. Rodriguez-Barrueco, A. Barsotti, A. Chicas, W. Li, A. Polotskaia, M. J. Bissell, T. F. Osborne, B. Tian, S.W. Lowe, J. M. Silva, A. L. Borresen-Dale, A. J. Levine, J. Bargonetti, and C. Prives, Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148, 244 (2012).
26. A. K. Iyer, G. Khaled, J. Fang, and H. Maeda, Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today. 11, 812 (2006).
27. S. Y. Park, B. R. Han, K. M. Na, D. K. Han, and S. C. Kim, Micellization and gelation of aqueous solutions of star-shaped PLLA-PEO block copolymers. Macromolecules 36, 4115 (2003).
28. T. B. Ren, Y. Feng, Z. H. Zhang, L. Li, and Y. Y. Li, Shellsheddable micelles based on star-shaped poly(epsilon-caprolactone)- SS-poly(ethyl glycol) copolymer for intracellular drug release. Soft Matter. 7, 2329 (2011).
29. X. Zeng, W. Tao, L. Mei, L. Huang, C. Tan, and S. S. Feng, Cholic acid-functionalized nanoparticles of star-shaped PLGA-vitamin E TPGS copolymer for docetaxel delivery to cervical cancer. Biomaterials 34, 6058 (2013).
30. P. M. Valencia, M. H. Hanewich-Hollatz, W. Gao, F. Karim, R. Langer, R. Karnik, and O. C. Farokhzad, Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticles. Biomaterials 32, 6226 (2011).
31. F. Yan, C. Zhang, Y. Zheng, L. Mei, L. Tang, C. Song, H. Sun, and L. Huang, The effect of poloxamer 188 on nanoparticle morphology, size, cancer cell uptake, and cytotoxicity. Nanomedicine 6, 170 (2010).
32. D. Š. L. Nováková and P. Solich, HPLC methods for the determination of simvastatin and atorvastatin. Trends Anal. Chem. 27, 352 (2008).
33. Y. Mi, J. Zhao, and S. S. Feng, Targeted co-delivery of docetaxel, cisplatin and herceptin by vitamin E TPGS-cisplatin prodrug nanoparticles for multimodality treatment of cancer. J. Control Release (2013).
34. F. Alexis, E. Pridgen, L. K. Molnar, and O. C. Farokhzad, Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 5, 505 (2008).
35. C. He, Y. Hu, L. Yin, C. Tang, and C. Yin, Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 31, 3657 (2010).
36. B. C. Hancock and M. Parks, What is the true solubility advantage for amorphous pharmaceuticals?. Pharm Res. 17, 397 (2000).
37. P. Gupta, G. Chawla, and A. K. Bansal, Physical stability and solubility advantage from amorphous celecoxib: The role of thermodynamic quantities and molecular mobility. Mol Pharm. 1, 406 (2004).
38. T. Motokura, T. Bloom, H. G. Kim, H. Juppner, J. V. Ruderman, H. M. Kronenberg, and A. Arnold, A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature 350, 512 (1991).